Clinical trial results in control (ST) patients receiving standard treatments showed a strong aggravation of the mean respiratory symptoms Leicester Cough Questionnaire (LCQ) and Visual analogue scale (VAS) parameters on days 1 and 2 followed by further slow deterioration up to day 4-6 and progressive improvement thereafter. In the test product group (TP, PIRDAL or Covispray),

treated with osmotic polymeric nasal film, the respiratory symptoms did not aggravate on days 1 and 2 but remained stable up to day 5 followed by slow improvement, parallel to the ST group, up to day 14. The mean LCQ and VAS score difference between the TP and the ST groups was statistically significant (p<0.05) from day 1 onwards. The reason for this stabilization of respiratory

symptoms immediately after the first treatment probably resides in the fact that the TP acts instantly by cleaning newly generated virus particles as well as inflammatory cytokines towards the film where they are trapped and inactivated by polymers. This mechanical cleaning minimizes cellular destruction and stimulates reconstruction of nasal mucosa. TP cleans only the free-floating nasal surface virus and protein molecules but has no effect on the intracellular and circulating virus particles which continue pouring onto the nasal surface and maintaining the infection for a few weeks. This explains why there is a sharp drop of Covid-19 clinical symptoms during the first 4-6 days, but further improvement is progressive and slow. The TP does not cure the disease but

strongly reduces clinical symptoms right after the 1 st treatment. This approach minimizes the probability of developing severe respiratory symptoms. The intensity of fever, loss of sense of taste, small, and headache were also reduced in the TP compared to ST group right after the start of 1 st treatment. 

Being a mechanically acting, non-specific nasal surface cleaner, the test product

should act against any Covid-19 viral mutant.